|
VRDN | Viridian Therapeutics, Inc.de |
|
|
VRDN | Viridian Therapeutics, Inc.de |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.43 |
| Leverage | 39.66% |
| Market Cap | $ 1.5B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -385.7m |
| Margin | -436.15% |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.